# A Phase 3 Study of HS-20094 in Patients With T2DM

Study · id `cardio:ct-nct07156539` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07156539](<https://clinicaltrials.gov/study/NCT07156539>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07156539

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 546 participants.

## Technical summary

Registry record NCT07156539. Randomized; no masking; primary purpose treatment. Start 2025-09-30 (anticipated); primary completion 2027-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 546 participants (planned count; ClinicalTrials.gov record NCT07156539, source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)
- Planned start: 2025-09-30 (anticipated) (ClinicalTrials.gov record NCT07156539, source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)
- Primary completion: 2027-03-30 (anticipated) (ClinicalTrials.gov record NCT07156539, source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)
- Completion: 2027-05-30 (anticipated) (ClinicalTrials.gov record NCT07156539, source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07156539, source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07156539-2025-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study of HS-20094 in Patients With T2DM
- Condition: Type 2 Diabetes
- Intervention (Drug): HS-20094 Injection
- Intervention (Drug): Dulaglutide Injection
- Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-hansoh-pharmaceutical-co-ltd`)

## Provenance

Content hash: 63125461f974a7c0e443bce49dd2de65cd6a4e6af13945c00dad5e4bb8d1441d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
